Exploring the real-world use of atezolizumab in Ontario, Canada

Summary

Client: Hoffmann-La Roche Limited

Project ID: P2023-204/ 2025 0970 391 000

Research Question/Objectives: Tecentriq (atezolizumab) is a type of cancer immunotherapy treatment with a number of approved indications in Canada, including hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC), and small cell lung cancer (SCLC). To understand the real-world use of atezolizumab—and determine the feasibility of conducting further RWD studies in the respective disease area cohorts–we sought to explore and extrapolate from the RWD available for the province of Ontario.

Objectives:

Primary Objective:

• To characterize the frequency and percentage of atezolizumab use, by indication and by month/year; and, where possible, broken down by:
  • Local Health Integration Network (LHIN)
  • New starts
  • Cumulative usage

Secondary Objectives:

• To describe the group of atezolizumab-treated HCC patients by:
  • Whether they received an upper endoscopy (esophagogastroduodenoscopy or EGD) anytime after diagnosis (%)
  • Duration of Tx (months between first and last atezolizumab)

Status: Completed

Results: August 2025